Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IL6 and lymphoproliferative disorders.

J C Brouet1, Y Levy

  • 1Laboratoire d'Immunochimie et d'Immunopathologie, U108 INSERM, Hôpital Saint-Louis, Paris, France.

Nouvelle Revue Francaise D'Hematologie
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cerebro-meningeal localization of extramedullary haematopoiesis (EMH), a rare complication of chronic idiopathic myelofibrosis (CIM).

Neuropathology and applied neurobiology·2004
Same author

Evaluation of bone mineral density and fat-lean distribution in patients with multiple myeloma in sustained remission.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2003
Same author

Interleukin-6 stimulates HHV-8 replication in bone marrow cultures and infected cell lines.

The hematology journal : the official journal of the European Haematology Association·2002
Same author

[Chronic lymphoid leukemia].

La Revue du praticien·2002
Same author

[A macroglobulinemia with an unusual bone marrow aspect].

Annales de pathologie·2001
Same author

Study of the B cell memory compartment in common variable immunodeficiency.

European journal of immunology·2000
Same journal

XIVth Congress of the French Society of Hematology. Paris, France, February 3-4, 1995. Abstracts.

Nouvelle revue francaise d'hematologie·1995
Same journal

Improved detection of CD2 on formaldehyde-fixed non dehydrated cells.

Nouvelle revue francaise d'hematologie·1995
Same journal

Engraftment of CD34+ peripheral blood progenitor cells into multiple myeloma patients following total body irradiation.

Nouvelle revue francaise d'hematologie·1995
Same journal

Allogeneic transplantation of peripheral blood progenitor cells.

Nouvelle revue francaise d'hematologie·1995
Same journal

Selection and expansion of CD34+ cells.

Nouvelle revue francaise d'hematologie·1995
Same journal

Ex vivo hematopoietic cell expansion: a theoretical and technological challenge.

Nouvelle revue francaise d'hematologie·1995
See all related articles

Interleukin 6 (IL6) drives multiple myeloma and Waldenström's macroglobulinemia progression. Inhibiting IL6 mRNA with antisense oligodeoxynucleotides reduced myeloma cell proliferation, highlighting IL6 as a therapeutic target.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Interleukin 6 (IL6) exhibits diverse effects across cell types.
  • IL6 is implicated in the pathogenesis of various hematological malignancies.
  • Autocrine or paracrine IL6 signaling may be crucial for tumor development.

Purpose of the Study:

  • To investigate the role of IL6 in multiple myeloma and other lymphoid malignancies.
  • To assess the therapeutic potential of targeting IL6 in these cancers.

Main Methods:

  • Utilized antisense oligodeoxynucleotides targeting IL6 mRNA.
  • Assessed the impact of IL6 inhibition on myeloma cell proliferation in vitro.
  • Reviewed existing data on IL6 involvement in Waldenström's macroglobulinemia, lymphomas, and Castleman disease.

Related Experiment Videos

Main Results:

  • Antisense targeting of IL6 mRNA significantly decreased proliferation in two myeloma cell lines.
  • IL6 autocrine signaling is critical for tumor cell differentiation in early-stage Waldenström's macroglobulinemia.
  • IL6 plays a role in the systemic symptoms of Castleman disease.

Conclusions:

  • IL6 is a key mediator in the development and progression of multiple myeloma.
  • Targeting IL6 represents a promising therapeutic strategy for multiple myeloma and related lymphoid malignancies.
  • IL6 is integral to the pathogenesis of Waldenström's macroglobulinemia and Castleman disease.